Search

Vincent S Gallicchio

from Belton, SC
Age ~76

Vincent Gallicchio Phones & Addresses

  • 106 Sentinel Rdg, Belton, SC 29627 (864) 328-9540
  • Central, SC
  • 2236 Bonhaven Rd, Lexington, KY 40515 (859) 271-9317
  • West Haven, CT
  • Clemson, SC

Work

Company: Verizon north inc - Lexington, KY 2002 Position: Directory assistance operator

Education

School / High School: Midway College Online- Midway, KY 2010 Specialities: psychology

Resumes

Resumes

Vincent Gallicchio Photo 1

Associate Vice President For Research At Clemson University Professor And Director At Clemson University

View page
Location:
Greenville, South Carolina Area
Industry:
Higher Education
Experience:
Clemson University (Higher Education industry): Associate Vice President for Research,  (-) Clemson University (Higher Education industry): Professor and Director,  (2005-Present) 
Vincent Gallicchio Photo 2

Vincent Gallicchio Lexington, KY

View page
Work:
Verizon North Inc
Lexington, KY
2002 to 2010
Directory Assistance Operator

Kmart
Lexington, KY
1993 to 2002
Electronics and Layaway Associate

Education:
Midway College Online
Midway, KY
2010 to 2000
psychology

Transylvania University
Lexington, KY
1993 to 1998

Tates Creek High School
Lexington, KY
1990 to 1993
Diploma

Vincent Gallicchio Photo 3

Vincent Gallicchio

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Vincent S. Gallicchio
Sole Officer
ACADEMIC ENTERPRISES, INC
2236 Bonhaven Rd, Lexington, KY 40515

Publications

Us Patents

Conjugate Of Biologically Active Compound And Polar Lipid Conjugated To A Microparticle For Biological Targeting

View page
US Patent:
6339060, Jan 15, 2002
Filed:
May 16, 2000
Appl. No.:
09/573497
Inventors:
Milton B. Yatvin - Portland OR
Michael H B Stowell - Cambridge, GB
Vincent S. Gallicchio - Lexington KY
Michael J. Meredith - Lake Oswego OR
Assignee:
Oregon Health Science University - Portland OR
International Classification:
A01N 3718
US Classification:
514 2, 424450, 435176, 435178, 435179, 435180, 435325, 435366, 530300, 530329, 530331, 530811, 530813, 530814, 530815
Abstract:
Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

Composition Containing Porous Microparticle Impregnated With Biologically-Active Compound For Treatment Of Infection

View page
US Patent:
6858582, Feb 22, 2005
Filed:
Jan 15, 2002
Appl. No.:
10/050271
Inventors:
Milton B. Yatvin - Portland OR, US
Michael HB Stowell - Fulbourn, GB
Vincent S. Gallicchio - Lexington KY, US
Michael J. Meredith - Lake Oswego OR, US
Assignee:
Oregon Health and Sciences University - Portland OR
International Classification:
A01N037/18
A61K009/127
A61K047/00
C12N005/08
C07K017/00
US Classification:
514 2, 424450, 435176, 435178, 435179, 435180, 435325, 435366, 530300, 530329, 530331, 530811, 530813, 530814, 530815
Abstract:
Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

Nonporous Microparticle-Prodrug Conjugates For Treatment Of Infection

View page
US Patent:
7423010, Sep 9, 2008
Filed:
Feb 22, 2005
Appl. No.:
11/064416
Inventors:
Milton Yatvin - Portland OR, US
Michael Stowell - Fulbourn, GB
Vincent Gallicchio - Lexington KY, US
Michael Meredith - Lake Oswego OR, US
Assignee:
Oregon Health & Science University - Portland OR
International Classification:
A01N 38/18
A61K 9/127
A61K 47/00
C12N 5/08
C07K 17/00
US Classification:
514 2, 424450, 435176, 435178, 435179, 435180, 435325, 435366, 530300, 530329, 530331, 530811, 530813, 530814, 530815
Abstract:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antiviral and antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via a cleavable linker moiety that is non-specifically cleaved in a phagocytic cell. In additional embodiments, the biologically-active compound is provided in an inactive, prodrug form that is activated by a chemical or enzymatic activity specific for cells infected by a microorganism, particularly a pathological or disease-causing microorganism.

Berry Preparations And Extracts

View page
US Patent:
7964223, Jun 21, 2011
Filed:
Sep 26, 2006
Appl. No.:
12/088156
Inventors:
Russell J. Mumper - Chapel Hill NC, US
Jin Dai - Carrboro NC, US
Vincent S. Gallicchio - Belton SC, US
Assignee:
University of Kentucky Research Foundation - Lexington KY
International Classification:
A01N 65/00
US Classification:
424725
Abstract:
A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4. 5, and recovering a berry extract having a stabilized anthocyanin content. The berry may be a blackberry. A cryoprotectant may be added, to further stabilize the anthocyanin content. Compositions comprising the berry extract of the present invention, formulated for oral and/or topical administration, are provided also, including nutritional supplements, capsules, enteric-coated capsules, film-coated capsules, tablets, enteric-coated tablets, film-coated tablets, chewing gums, lotions, creams, mucoadhesive gels, vanishing lotions, vanishing creams, and the like. In yet another aspect, the present invention provides methods and compositions for treating inflammation, oxidative damage, or cancer in a mammal.

Berry Preparations And Extracts

View page
US Patent:
8367126, Feb 5, 2013
Filed:
Jun 10, 2011
Appl. No.:
13/157531
Inventors:
Russell J. Mumper - Chapel Hill NC, US
Jin Dai - Lexington KY, US
Vincent S. Gallicchio - Belton SC, US
Assignee:
University of Kentucky Research Foundation - Lexington KY
International Classification:
A61K 36/00
A61K 36/45
US Classification:
424725, 424732, 424777
Abstract:
Compositions having antioxidant and anti-inflammatory activity, and methods for providing such compositions, are disclosed. In one aspect, the compositions are derived by exposing a berry to an acidic solvent composition, adding a cryoprotectant, and recovering a berry extract having a stabilized anthocyanin content. Compositions comprising the stabilized anthocyanin-containing berry extract, formulated for oral and/or topical administration, are provided also.

Covalent Microparticle-Drug Conjugates For Biological Targeting

View page
US Patent:
58406743, Nov 24, 1998
Filed:
Aug 1, 1996
Appl. No.:
8/691891
Inventors:
Milton B. Yatvin - Portland OR
Michael H. B. Stowell - Padadena CA
Vincent S. Gallicchio - Lexington KY
Michael J. Meredith - Lake Oswego OR
Assignee:
Oregon Health Sciences University - Portland OR
International Classification:
A01N 3718
A01N 5726
US Classification:
514 2
Abstract:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antiviral and antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism.

Covalent Microparticle-Drug Conjugates For Biological Targeting

View page
US Patent:
55433910, Aug 6, 1996
Filed:
May 16, 1995
Appl. No.:
8/441770
Inventors:
Milton B. Yatvin - Portland OR
Michael H. B. Stowell - Pasadena CA
Vincent S. Gallicchio - Lexington KY
Michael J. Meredith - Lake Oswego OR
Assignee:
State of Oregon, Acting by and Through the Oregon State Board of Higher
Education, Acting for and on Behalf of the Oregon Health Sciences
University - Portland OR
International Classification:
A01N 3718
A01N 5726
US Classification:
514 2
Abstract:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism.

Conjugate Of Biologically Active Compound And Polar Lipid Conjugated To A Microparticle For Biological Targeting

View page
US Patent:
60637595, May 16, 2000
Filed:
Apr 14, 1998
Appl. No.:
9/060011
Inventors:
Milton B. Yatvin - Portland OR
Michael H B Stowell - Fulbourn, GB
Vincent S. Gallicchio - Lexington KY
Michael J. Meredith - Lake Oswego OR
Assignee:
Oregon Health Sciences University - Portland OR
International Classification:
A01N 3718
A61K 9127
A61K 4700
C12N 508
C07K 1700
US Classification:
514 2
Abstract:
Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

Isbn (Books And Publications)

Lithium and Cell Physiology

View page
Author

Vincent S. Gallicchio

ISBN #

0387971289

Lithium and the Blood

View page
Author

Vincent S. Gallicchio

ISBN #

3805552793

Vincent S Gallicchio from Belton, SC, age ~76 Get Report